News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Each year, Life Sciences PA hosts a celebration to honor the innovation and commitment members have made to the life sciences industry.
REGENXBIO was co-founded by James Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine.
Aspaveli ® is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally.
GEMMA announced that its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil.
Initial trial data is expected in the second half of 2026.
The company is currently raising $8.5 million to support further development of its diagnostic and prognostic tools.
Vasowatch received $150K from Ben Franklin Technology Partners.
Linnaeus will use these funds to further develop LNS880.
PCI hosted its annual Innovation @ Penn program at Wharton San Francisco.
The dedicated venture capital fund will invest in early-stage life science companies spun out of Penn.